Drug Development, Tax Breaks, Future Reimbursement Expected After Medical Marijuana …
Federal policy changes around cannabis drug development tax incentives could reshape medical cannabis access and research funding. Understanding these regulatory shifts helps clinicians prepare for evolving therapeutic landscapes while maintaining focus…
Understanding the Legal Risks of the CMS Hemp CBD Program Lawsuit
The CMS hemp CBD program lawsuit poses significant legal risks affecting healthcare coverage and reimbursement. This litigation highlights regulatory uncertainty around hemp-derived CBD. Understanding these risks is crucial for clinicians and patients…
CMS Sets A 2.48% Medicare Advantage Payment Rate Increase For 2027
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic MedicareInsurance CoverageHealthcare…
U.S. Launches Medicare’s Pilot Hemp Program – Shanken News Daily
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic MedicarePolicyCbdAccessReimbursement Why…
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule | Insights | Holland & Knight
CMS has finalized the Medicare Advantage payment rate increase for 2027, a key update affecting healthcare access for over 65 million Americans. This change influences reimbursement policies and patient care options, including those related to cannabis…
Trump Administration Announces New Medicare CBD Coverage Details
The Trump administration has released Medicare CBD coverage details that could affect cannabinoid reimbursement. This update signals federal recognition of cannabinoids in healthcare. Medicare coverage decisions will influence access to CBD therapies for…